Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

HSCI and Stock Connect - Biotech Stocks Now Eligible; Inclusion & Exclusion Possibilities

HSCI Index Rebalance - Stock Connect Flows Coming Up

Wuxi Biologics Placement - Another One Before Lock-Up, but Just in Time for the Index Inclusion

CanSino Biologics (康希诺) IPO Trading Update - Time to Cash Out

CanSino Biologics (康希诺) IPO: Valuation Attractive, Lilly Asia Doubling Up (Part 4)

CanSino Biologics (康希诺) IPO: Valuation Update (Part 3)

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

CanSino Biologics  / Equity Capital Markets

<p>CanSino Biologics' shareholder Lilly Asia Venture is selling USD 76 million worth of stake in CanSino Biologics. In this insight, we will take a quick look at the fundamentals of the company, and provide our thoughts on the deal. </p>

CanSino Biologics' shareholder Lilly Asia Venture is selling USD 76 million worth of stake in CanSino Biologics. In this insight, we will take a quick look at the fundamentals of the company, and provide our thoughts on the deal. 

CanSino Biologics Placement: Liquidity Permits a Trade but Beware of COVID-19 Hype